Kyoto University
- Country
- 🇯🇵Japan
- Ownership
- Private
- Established
- 1900-01-01
- Employees
- 1K
- Market Cap
- -
- Website
- http://www.kyoto-u.ac.jp
Clinical Trials
308
Trial Phases
5 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (303 trials with phase data)• Click on a phase to view related trials
Optimal PERioperative Antiplatelet Therapy Investigation ON Abdominal Surgery After Coronary Stent Implantation
- Conditions
- Antiplatelet AgentsPerioperative Care
- Interventions
- First Posted Date
- 2024-12-09
- Last Posted Date
- 2025-02-11
- Lead Sponsor
- Kyoto University
- Target Recruit Count
- 1200
- Registration Number
- NCT06723145
- Locations
- 🇯🇵
Kyoto University Hospital, Kyoto, Japan
iPSC-based Drug Repurposing for ALS Medicine (iDReAM) Study
- Conditions
- Amyotrophic Lateral Sclerosis
- Interventions
- First Posted Date
- 2021-02-09
- Last Posted Date
- 2023-03-08
- Lead Sponsor
- Kyoto University
- Target Recruit Count
- 49
- Registration Number
- NCT04744532
- Locations
- 🇯🇵
Hiroshima University, Hiroshima, Japan
🇯🇵Nara Medical University, Kashihara, Japan
🇯🇵Kyoto University, Kyoto, Japan
Repurposing Bromocriptine for Abeta Metabolism in Alzheimer's Disease
- Conditions
- PSEN1 MutationFamilial Alzheimer Disease (FAD)
- Interventions
- Drug: Placebos
- First Posted Date
- 2020-06-02
- Last Posted Date
- 2022-04-07
- Lead Sponsor
- Kyoto University
- Target Recruit Count
- 8
- Registration Number
- NCT04413344
- Locations
- 🇯🇵
Nagoya City University Hospital, Nagoya, Aichi, Japan
🇯🇵Mie University Hospital, Tsu, Mie, Japan
🇯🇵Kawasaki Medical School Hospital, Kurashiki, Okayama, Japan
Extended Japan Assessment of Pitavastatin and Atorvastatin in Acute Coronary Syndrome
- Conditions
- StatinCoronary PlaqueAcute Coronary SyndromeIntravascular UltrasoundCardiovascular Events
- First Posted Date
- 2010-10-19
- Last Posted Date
- 2012-04-24
- Lead Sponsor
- Kyoto University
- Target Recruit Count
- 238
- Registration Number
- NCT01223586
- Locations
- 🇯🇵
Division of Cardiology, Department of Medicine and Clinical Science, Yamaguchi University Graduate School of Medicine, Ube, Yamaguchi, Japan
🇯🇵Division of Cardiology, Kyoto University Hospital, Kyoto, Japan
Strategic Use of New Generation Antidepressants for Depression
- Conditions
- Unipolar Major Depressive Episode
- Interventions
- First Posted Date
- 2010-04-23
- Last Posted Date
- 2016-10-03
- Lead Sponsor
- Kyoto University
- Target Recruit Count
- 2011
- Registration Number
- NCT01109693
- Locations
- 🇯🇵
Nagoya City University Hospital, Nagoya, Aichi, Japan
🇯🇵Kochi Medical School Hospital, Nangoku, Kochi, Japan
- Prev
- 1
- 2
- 3
- 4
- 5
- Next
News
Heart Drug Cilostazol Shows Promise for Treating Growth Disorders in Preclinical Study
Researchers discovered that phosphodiesterase 3 (PDE3) inhibitors, currently used for heart disease and thrombosis, can stimulate bone growth by enhancing calcium influx into bone cells.
Japanese Researchers Launch Final Phase Trial of Bromocriptine for Familial Alzheimer's Disease
Towa Pharmaceutical and Kyoto University have initiated the final phase of a clinical trial testing bromocriptine, a Parkinson's drug, as a potential treatment for familial Alzheimer's disease using innovative iPS drug discovery methods.
Denosumab Shows Superior Fracture Prevention in Dialysis Patients Despite Cardiovascular Risks
Japanese study reveals denosumab reduces fracture risk by 45% compared to oral bisphosphonates in dialysis patients over three years, particularly effective for nonvertebral fractures.
Experimental Drug Shows Promise in Regenerating Teeth in Human Trials
Japanese researchers are testing a drug aimed at regenerating teeth, with human trials commencing this September.
Rege Nephro Secures $150 Million in Series B Funding to Advance Kidney Disease Therapies
Rege Nephro has successfully raised $22.5 billion yen ($150 million) in Series B funding to advance clinical trials for kidney disease therapies.